Exploring the Relationship Between Type 2 Diabetes Medications and Autoimmune Disease Risk
Overview:
Individuals with type 2 diabetes who are prescribed medications such as glucagon-like peptide 1 receptor agonists (GLP-1-RAs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP-4) inhibitors show no variation in the likelihood of developing autoimmune disease.
Research Methodology:
Previous case reports and limited studies have suggested a potential link between GLP-1-RAs and SGLT2 inhibitors with autoimmune rheumatic disease (ARD). To further investigate, a study analyzed health data from 2014 to 2021, focusing on 34,400 GLP-1-RA users and 83,500 SGLT2 inhibitor users. The comparison group consisted of 68,400 DPP-4 inhibitor users. The primary outcome measured was the occurrence of ARD based on medical diagnosis codes.
Key Findings:
The study revealed that there were no significant disparities in new ARD diagnoses among the different medication groups. The average follow-up duration ranged from 0.88 to 1.53 years. The hazard ratio (HR) for ARDs associated with GLP-1-RAs was 0.93 (95% CI, 0.66-1.30) compared to DPP-4 inhibitors, while the HR for SGLT2 inhibitors was 0.97 (95% CI, 0.76-1.24).
Implications:
The need for extended longitudinal data is emphasized to fully understand the long-term effects of these medications on autoimmune disease risk. Additional research is crucial to determine the balance between benefits and potential risks associated with prolonged exposure.
Presentation and Limitations:
Dr. Derin Karacabeyli of the University of British Columbia presented these findings at the Canadian Rheumatology Association (CRA) 2024 Annual Meeting. It is essential to acknowledge that the study’s observational nature may introduce residual or unmeasured confounding variables. The reliance on diagnostic codes and the relatively short follow-up period are also identified as limitations.
Financial Support and Disclosures:
Funded by the Canadian Institutes of Health Research, the study had no conflicts of interest disclosed by the authors. The study sheds light on the complex interplay between type 2 diabetes medications and autoimmune disease development, offering valuable insights for future research and clinical practice.